Figure 5

Lateral swelling abilities of (A) and dissolution profiles of alendronate in simulated gastric fluid (SGF) from (B) FOSAMAX and tablets prepared with ring-opened polyvinyl pyrrolidone (roPVP)/chitosan (CS) hydrogels composed of roPVP complexed with either low molecular weight (Mw) CS, medium Mw CS, or high Mw CS at a roPVP:CS ratio of 20:1. (C) Plasma alendronate concentration profiles after administration of FOSAMAX and a gastroretentive drug delivery formulation (GRDDF) (H20-1) (mean ± SD, n = 3) for 72 h.